Merck KGaA (MRK.DE) News and Global Science & Technology Innovation Updates
Merck KGaA, headquartered in Darmstadt, Germany, is a multinational science and technology company with operations in healthcare, life sciences, and performance materials (electronics). Its businesses include pharmaceuticals, laboratory supplies, and specialty chemicals for electronics and semiconductors. Merck is focused on research-driven innovation in oncology, immunology, bioprocessing, and next-generation electronics.
127.06
2.3250
1.80 %
Real-time price
11:00
USD
Daily range
126.90
127.92
127.92
Weekly range
119.51
129.94
129.94
Merck stock jumps 2.31% as company expands HIV treatment access through ADAPs
Merck announced an agreement with the AIDS Crisis Task Force to provide increased access to HIV treatment for eligible people living with HIV through state AIDS Drug Assistance Programs.The ...
Merck stock slides amid strong selling pressure despite Phase 3 immunology trial update
Merck reported positive topline results from a Phase 3 induction-only study in patients with moderately to severely active ulcerative colitis.The company stated these results reinforce its ongoing ...
Merck stock drops 1.25% as company posts strong Phase 3 HIV data with Gilead Sciences
Merck announced positive topline Phase 3 results for its investigational once-weekly HIV treatment for adults with virologically suppressed HIV.The results come from a collaboration with Gilead ...
Merck stock price forecast: bullish bias and tight range as MRK holds near highs
Merck announced that the FDA has granted Priority Review for a new treatment option for certain patients with extensive-stage small cell lung cancer.Merck is collaborating with Daiichi Sankyo on ...
Phase 3 results drive Merck stock higher amid weak momentum and strong resistance ahead
Merck shared Phase 3 results of its investigational oral macrocyclic peptide at #ACC26.The company provided a link for more information. Details are being clarified.[highlights-block]MRK (€) is ...
Phase 2 study update lifts Merck stock amid overbought signals and bullish trend
Merck is sharing data for its Phase 2 study in an uncommon type of pulmonary hypertension at #ACC26.A link to read more has been provided in the announcement. Details are being ...
+0.38% for Merck stock as price remains below key moving averages
Merck announced an agreement to acquire Terns Pharmaceuticals. The deal will add a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia to Merck's ...
Merck expands presence in hematology with Terns Pharma acquisition
Merck has announced an agreement to acquire Terns Pharma, a move aimed at expanding its portfolio in the hematology field. The deal will add a potential best-in-class treatment candidate for ...
Merck unveils new evidence on HPV at EUROGIN 2026
Merck will present long term data on human papillomavirus (HPV) at EUROGIN 2026, underscoring its ongoing commitment to patient outcomes. The company intends to spotlight the significance of this ...
Merck stock forecast for 2030: Can division overhaul and late-stage surge push MRK to $180?
Merck divided its pharmaceutical operations on February 23. The organization revealed its plan to reorganize the Human Health division into two independent entities: a dedicated Oncology sector ...
Merck announces Phase 3 trial results for new HIV treatment at CROI2026
Merck has unveiled new results from three Phase 3 clinical trials evaluating its investigational HIV treatment during the CROI2026 conference. The trials reflect ongoing research efforts to ...
Merck unveils Phase 3 data for new peptide treatment
Merck has unveiled the first-time results of its Phase 3 study for an investigational oral macrocyclic peptide. The announcement was made at the American Heart Association's annual event, AHA25, ...
Merck: Low volatility and sideways trend led to neutral price forecast
Merck KGaA (MRK) is trading at $114.90, positioned just above both the MA-20 at $114.61 and the MA-50 at $111.36, but well below the MA-200 at $120.56. This setup signals short- and medium-term ...
Merck price forecast: sideways ahead? Rally stalls near resistance at $115.75
Merck KGaA (MRK) is now trading at $115.15, positioning above both the MA-20 ($114.43) and MA-50 ($111.28), but still below the long-term MA-200 ($120.69). This signals short- and medium-term ...
MRK latest news: Trades above MA-50 support — sellers face near-term technical headwinds
Merck KGaA (MRK) is currently trading at $113.35, sitting below the MA-20 ($114.19) and well under the MA-200 ($120.84), yet remaining above the MA-50 ($111.18). This positioning signals ...
Merck unveils long-term data for lung cancer immunotherapy
Merck has announced the release of long-term follow-up data regarding their immunotherapy option for non-small cell lung cancer patients. This information was shared at the European Society for ...
